Russell Investments Group
CADL icon

Russell Investments Group’s Candel Therapeutics CADL Stock Holding History

Russell Investments Group’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.1K Sell
3,700
-463
-11% -$2.52K ﹤0.01% 3648
2025
Q4 		$23.5K Buy
4,163
+905
+28% +$4.87K ﹤0.01% 3573
2025
Q3 		$16.6K Buy
+3,258
New +$18.8K ﹤0.01% 3647
2025
Q2 		– Sell
-4,732
Closed -$26.7K – 3856
2025
Q1 		$26.7K Buy
4,732
+979
+26% +$8K ﹤0.01% 3048
2024
Q4 		$32.6K Buy
3,753
+1,610
+75% +$9.51K ﹤0.01% 2917
2024
Q3 		$14.9K Buy
+2,143
New +$13.3K ﹤0.01% 3016

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Russell Investments Group's CADL Position: Q1 2026 in Review

Russell Investments Group reduced its Candel Therapeutics (CADL) stake by 11% in Q1 2026, selling an estimated $2.52K and leaving 3,700 shares worth $18.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3648.

Russell Investments Group first reported a position in CADL in Q3 2024 and has held it in 6 quarters since. The position peaked at $32.6K in Q4 2024. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Russell Investments Group held 3,700 shares of Candel Therapeutics worth $18.1K as of Q1 2026.
  • Russell Investments Group sold 463 Candel Therapeutics shares in Q1 2026, an estimated $2.52K.
  • Candel Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #3648 holding.
  • Russell Investments Group first reported a position in Candel Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • Russell Investments Group's Candel Therapeutics position peaked at $32.6K in Q4 2024.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.